menu
    • menu
    [{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Children's Hospital of Philadelphia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital of Philadelphia \/ Undisclosed"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Amylyx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Amylyx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Amylyx Pharmaceuticals"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Children's Hospital of Philadelphia","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Children's Hospital of Philadelphia","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Children's Hospital of Philadelphia"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Amylyx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Amylyx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Amylyx Pharmaceuticals"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Tracey McLaughlin","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Tracey McLaughlin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tracey McLaughlin \/ Eiger BioPharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Tracey McLaughlin \/ Eiger BioPharmaceuticals"},{"orgOrder":0,"company":"Tracey McLaughlin","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tracey McLaughlin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tracey McLaughlin \/ Eiger BioPharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Tracey McLaughlin \/ Eiger BioPharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Avexitide

    Menu

    Avexitide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amylyx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Amylyx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Leerink Partners

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering

                            Details : The net proceeds will be used for the future development of Avexitide, a novel, first-in-class GLP-1 receptor antagonist with the potential to treat post-bariatric hypoglycemia.

                            Product Name : Exendin 9-39

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            September 10, 2025

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Leerink Partners

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amylyx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Amylyx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Leerink Partners

                            Deal Size : $60.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

                            Details : The net proceeds will used to support the company's late-stage product Exendin 9-39 (avexitide). It is being evaluated for the treatment of Post Bariatric Hypoglycemia.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            January 10, 2025

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Leerink Partners

                            Deal Size : $60.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amylyx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Amylyx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Leerink Partners

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

                            Details : The net proceeds will used to support the company's late-stage product Exendin 9-39 (avexitide). It is being evaluated for the treatment of Post Bariatric Hypoglycemia.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Leerink Partners

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Amylyx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Amylyx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avexitide for Treatment of Post-Bariatric Hypoglycemia

                            Details : Avexitide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Post-Bariatric, Hypoglycemia.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 24, 2024

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Amylyx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Amylyx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amylyx Unveils Phase 3 LUCIDITY Trial Design for Avexitide in Post-Bariatric Hypoglycemia

                            Details : Amylyx Pharmaceuticals acquires Eiger BioPharmaceuticals' experimental drug Avexitide, GLP-1 antagonist. Currently, it is being evaluated for the treatment of Post Bariatric Hypoglycemia.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 04, 2024

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eiger BioPharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Eiger BioPharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Amylyx Pharmaceuticals

                            Deal Size : $35.1 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Amylyx Acquires Phase 3-Ready GLP-1 Receptor Antagonist (Avexitide)

                            Details : Amylyx Pharmaceuticals acquires Eiger BioPharmaceuticals' experimental drug Avexitide, GLP-1 antagonist. Currently, it is being evaluated for the treatment of Post Bariatric Hypoglycemia.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            July 10, 2024

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Amylyx Pharmaceuticals

                            Deal Size : $35.1 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eiger BioPharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Eiger BioPharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Amylyx Pharmaceuticals

                            Deal Size : $35.1 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar

                            Details : Amylyx Pharmaceuticals will acquire Eiger BioPharmaceuticals' experimental drug Avexitide, GLP-1 antagonist. Currently, it is being evaluated for the treatment of Post Bariatric Hypoglycemia.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            June 22, 2024

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Amylyx Pharmaceuticals

                            Deal Size : $35.1 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Eiger BioPharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Eiger BioPharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Ba...

                            Details : Results of avexitide (Exendin 9-39) in patients with PBH and hyperinsulinemic hypoglycemia (HH) after other gastrointestinal surgeries, demonstrating statistically significant reductions in hypoglycemia and meeting the primary and secondary endpoints of ...

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            June 13, 2022

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Eiger BioPharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Eiger BioPharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Children's Hospital of Philadelphia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulini...

                            Details : Phase 2 study demonstrating avexitide, an investigational, first-in-class glucagon-like peptide-1 receptor (GLP-1r) antagonist significantly reduced hypoglycemia in children with congenital hyperinsulinism published in Diabetes Care.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 25, 2022

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Children's Hospital of Philadelphia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Children's Hospital of Philadelphia

                            Country arrow
                            AAPS
                            Not Confirmed

                            Children's Hospital of Philadelphia

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment Developed by CHOP Researchers Prevents Hypoglycemia in Children with Hyperinsulinism

                            Details : In a phase 2a study, CHOP researchers showed exendin-(9-39) leads to blood sugar control in children with HI, which could improve care for a rare condition with few treatments.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 13, 2022

                            Lead Product(s) : Avexitide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth